Davis Polk advised the sole placing agent for the placement of 30,000,000 new shares in Akeso, Inc., for an aggregate consideration of approximately HK$1.19 billion.
Davis Polk also advised the underwriters on Akeso, Inc.’s HK$2.97 billion IPO in April 2020.
Akeso, Inc. is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. Since the company’s establishment, the company has established a comprehensive end-to-end drug development platform, ACE Platform, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC process development and GMP-compliant commercial scale manufacturing.
The Davis Polk team included partners James C. Lin and Yang Chu, counsel Xuelin (Steve) Wang and associate Lillian Lian. All members of the Davis Polk team are based in the Hong Kong office.